











ORIGINAL RESEARCH

# Long-Term Blood Pressure Variability and Risk of Cognitive Decline and Dementia Among Older Adults

Michael E. Ernst , PharmD; Joanne Ryan , PhD; Enayet K. Chowdhury, MBBS, MPH, PhD; Karen L. Margolis , MD; Lawrence J. Beilin, MB, MD; Christopher M. Reid , PhD; Mark R. Nelson , MBBS, PhD; Robyn L. Woods , PhD; Raj C. Shah, MD; Suzanne G. Orchard, PhD; Rory Wolfe, PhD; Elsdon Storey, MBBS, DPhil; Andrew M. Tonkin , MBBS, MD; Amy Brodtmann , MBBS, PhD; John J. McNeil , MBBS, PhD; Anne M. Murray , MD, MSc

**BACKGROUND:** Blood pressure variability (BPV) in midlife increases risk of late-life dementia, but the impact of BPV on the cognition of adults who have already reached older ages free of major cognitive deficits is unknown. We examined the risk of incident dementia and cognitive decline associated with long-term, visit-to-visit BPV in a post hoc analysis of the ASPREE (Aspirin in Reducing Events in the Elderly) trial.

**METHODS AND RESULTS:** ASPREE participants (N=19 114) were free of dementia and significant cognitive impairment at enrollment. Measurement of BP and administration of a standardized cognitive battery evaluating global cognition, delayed episodic memory, verbal fluency, and processing speed and attention occurred at baseline and follow-up visits. Time-to-event analysis using Cox proportional hazards regression models were used to calculate hazard ratios (HR) and corresponding 95% CI for incident dementia and cognitive decline, according to tertile of SD of systolic BPV. Individuals in the highest BPV tertile compared with the lowest had an increased risk of incident dementia and cognitive decline, independent of average BP and use of antihypertensive drugs. There was evidence that sex modified the association with incident dementia (interaction  $P=0.02$ ), with increased risk in men (HR, 1.68; 95% CI, 1.19–2.39) but not women (HR, 1.01; 95% CI, 0.72–1.42). For cognitive decline, similar increased risks were observed for men and women (interaction  $P=0.15$ ; men: HR, 1.36; 95% CI, 1.16–1.59; women: HR, 1.14; 95% CI, 0.98–1.32).

**CONCLUSIONS:** High BPV in older adults without major cognitive impairment, particularly men, is associated with increased risks of dementia and cognitive decline.

**REGISTRATION:** URL: <https://www.clinicaltrials.gov>; Unique identifier: NCT01038583; isrctn.com. Identifier: ISRCTN83772183.

**Key Words:** blood pressure ■ blood pressure variability ■ cognitive impairment ■ dementia

## See Editorial by McCormick

Increased longevity and a decline in fertility in recent decades have led to an aging global population. It is estimated that people aged 60 years and

older will outnumber adolescents and youth by 2050.<sup>1</sup> As an age-related disease, dementia has become a major public health concern worldwide, and the lack of

Correspondence to: Michael E. Ernst, PharmD, Department of Family Medicine, 01291-A PFP, The University of Iowa, 200 Hawkins Dr, Iowa City, IA 52242.  
E-mail: michael-ernst@uiowa.edu

This manuscript was sent to Sean Savitz, MD, Guest Editor, for review by expert referees, editorial decision, and final disposition.

A portion of this work was presented as a virtual poster abstract at the American Heart Association Hypertension Scientific Sessions, September 10 to 13, 2020.

Supplementary Material for this article is available at <https://www.ahajournals.org/doi/suppl/10.1161/JAHA.120.019613>

For Sources of Funding and Disclosures, see page 10.

© 2021 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

JAHA is available at: [www.ahajournals.org/journal/jaha](http://www.ahajournals.org/journal/jaha)

## CLINICAL PERSPECTIVE

### What Is New?

- We explored the association of long-term, visit-to-visit blood pressure variability with risk of incident dementia and cognitive decline in a generally healthy cohort of older adults who were enrolled in the ASPREE (Aspirin in Reducing Events in the Elderly) trial.
- Because ASPREE was not a blood pressure intervention study, and included adults who were normotensive and hypertensive, investigating blood pressure variability and its risks in this cohort potentially increases the generalizability of the findings to a broader population of older adults.

### What Are the Clinical Implications?

- We observed increased risks of incident dementia and cognitive decline, which were independent of average blood pressure and use of antihypertensive drugs, for individuals in the highest blood pressure variability tertile compared with the lowest.
- There was evidence of interaction by sex, with men demonstrating the most increased risk of dementia and cognitive decline; it remains uncertain whether reducing blood pressure variability can protect from the development of cognitive decline.
- Sex is emerging as a key biological variable in cerebrovascular and cardiovascular research; our findings highlight the need for further research into the potential mechanisms underlying sex-specific differences in diseases of aging.

## Nonstandard Abbreviations and Acronyms

<b>ASPREE</b>	Aspirin in Reducing Events in the Elderly
<b>BPV</b>	blood pressure variability

disease-modifying treatments ensures it will indefinitely remain a public health priority.

Hypertension is highly prevalent in midlife and is a strong risk factor for late-life cognitive decline and dementia.<sup>2-4</sup> Although the duration and severity of hypertension are important etiologies,<sup>2-7</sup> the short- and long-term fluctuation, or variability, of blood pressure (BP) has emerged as a novel risk factor for cognitive impairment and Alzheimer's disease.<sup>8-16</sup> However, previous studies examining high BP variability (BPV) and cognitive outcomes had limitations. These include using a single cognitive assessment

or instrument,<sup>12</sup> analyzing the relationship within predominantly younger cohorts,<sup>6,7,9-11,16</sup> in cohorts at high risk of cardiovascular disease and receiving antihypertensive drugs,<sup>14</sup> or in individuals with established cognitive impairment.<sup>16</sup>

Short-term BPV can be ascertained through 24-hour BP monitoring, but it is an assessment not routinely used in clinical practice.<sup>17</sup> Office BPs accumulated over multiple visits are more readily accessible, and an estimate of long-term BPV can be obtained from these readings.<sup>18</sup> In adults who have already reached advanced aged with preserved cognition and in otherwise good health, it is unknown whether long-term BPV is relevant to predicting their cognitive trajectory during their remaining lifespan. As a possible clinically actionable biomarker, there is a need for research to determine the extent that long-term BPV, beyond that of routine BP, can identify older adults at increased risk of cognitive impairment. Large cohorts with standardized assessments of BP and cognition conducted in parallel throughout long-term follow-up are required to address this research gap. The ASPREE (Aspirin in Reducing Events in the Elderly) study<sup>19</sup> is a longitudinal cohort uniquely suited to answer this question.

We examined the risk of incident dementia and cognitive decline associated with long-term, visit-to-visit BPV in participants of ASPREE, a randomized primary prevention trial of daily low-dose aspirin conducted in 19 114 older adults who were free from dementia, significant cognitive impairment, disability, or prior cardiovascular disease events, at baseline.

## METHODS

The data (version 3.0) that support the findings of this study are available from the ASPREE Data Coordinating Center, Monash University School of Public Health (Aspree.AMS@monash.edu) upon reasonable request.

### Study Participants

The detailed methods of ASPREE, its recruitment, and primary outcomes have been previously reported.<sup>19-21</sup> Briefly, ASPREE enrolled community-dwelling adults aged 70 years and older from Australia and the United States (65 years and older if US minority) from March 2010 to December 2014 and randomized them to aspirin 100 mg daily or matching placebo. At enrollment, participants were free of documented evidence of dementia, significant physical disability, prior cardiovascular events, as well as any medical condition expected to limit life expectancy to <5 years. Individuals with uncontrolled high BP (systolic BP  $\geq 180$  mm Hg and/or diastolic BP  $\geq 105$  mm Hg), or

a Modified Mini-Mental State Examination score of <78 were ineligible. All participants provided written informed consent for their participation, and the study was approved by institutional review boards in both countries. After a median follow-up of 4.7 years, aspirin did not extend disability-free survival<sup>21</sup>—a composite of death, incident dementia, or persistent physical disability—nor did it lower the risk of cognitive decline.<sup>22</sup>

### Standard Assessments

After completing baseline visits, participants were contacted quarterly by telephone and seen annually in person for clinical assessments by trained study staff following standard operating procedures. These assessments gathered data on physical function, lifestyle, anthropometrics, cognition, disability, and other health parameters, including medical diagnoses and prescription medications.

A standardized cognitive battery was administered at the baseline and at regular intervals over follow-up visits. The battery consisted of the Modified Mini-Mental State Examination for global cognition,<sup>23</sup> the Hopkins Verbal Learning Test-Revised for delayed episodic memory,<sup>24</sup> the single letter (F) Controlled Oral Word Association Test for verbal fluency,<sup>25</sup> and the Symbol Digit Modalities Test for processing speed and attention.<sup>26</sup> The 10-item Center for Epidemiologic Studies-Depression scale was administered before the cognitive battery to account for the possible confounding effect of depression on cognitive function.

### Assessment of Visit-to-Visit BPV

Blood pressure was measured at each study visit according to American Heart Association guidelines, in the seated position after at least 5 minutes of rest using a validated automated oscillometric device with an occluding cuff of appropriate size for the upper arm circumference.<sup>27</sup> Three separate and consecutive BP readings 1 minute apart were taken in a single arm. Consistent with the main ASPREE study reports, the average of all 3 measurements in each participant was recorded as the BP for that visit.

Several methods to estimate BPV have been used to characterize both short-term and long-term variability, with no universal consensus on the best measure.<sup>18</sup> Long-term, visit-to-visit BPV is usually estimated using the SD<sup>18</sup>; therefore, we estimated BPV initially using the within-individual SD of mean systolic BP obtained from the baseline, first-, and second-year annual visits. Sensitivity analyses were also undertaken to assess the robustness of the results, using the coefficient of variation and average real variability to estimate BPV, as well as expanding the SD estimate of BPV to 4

measures (baseline, first-, second-, and third-year annual visits), and then analyzing events occurring after the third annual visit. Lastly, we also explored the relationship between diastolic BPV and incident dementia and cognitive decline, estimating diastolic BPV in a similar manner as our primary BPV estimate.

### Cognitive Outcomes

The protocol for clinical adjudication of incident dementia in ASPREE has been reported previously.<sup>22</sup> Suspected dementia “triggers” were identified by a Modified Mini-Mental State Examination score <78 or a drop of >10.15 points from baseline (adjusted for age and education), or medical record report of dementia or memory problems, or prescription for cholinesterase inhibitor. Following a trigger, additional standardized cognitive and functional assessments were conducted whenever possible, which included the Alzheimer’s Disease Assessment Scale—Cognitive subscale,<sup>28</sup> Color Trails,<sup>29</sup> Lurian overlapping figures,<sup>30</sup> and the Alzheimer Disease Cooperative Study Activities of Daily Living Scale.<sup>31</sup> Clinical case notes and other supporting documentation were also obtained for these dementia triggers. All information was reviewed by an expert panel, blinded to treatment arm, who adjudicated the dementia end point using the *Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition* criteria.<sup>32</sup>

Because individuals could experience deterioration in cognitive function without meeting the threshold for referral for further testing, we also separately examined a broader outcome of incident cognitive decline. This was defined as a >1.5 SD decline in score from an individual’s baseline on any of the cognitive tests (Modified Mini-Mental State Examination, Symbol Digit Modalities Test, Hopkins Verbal Learning Test-Revised delayed recall, and/or Controlled Oral Word Association Test) during follow-up and sustained over 2 testing time points.<sup>22</sup>

### Statistical Analysis

Cox proportional hazards regression models with time-to-event analysis were used to calculate hazard ratios (HR) and corresponding 95% CI for incident dementia, using BPV as a continuous variable, and then according to tertile of BPV. The proportional hazards assumption was checked using Schoenfeld residuals and found to be appropriate. Year 2 was used as the new baseline. Tertiles were defined initially for the entire sample and then separately for men and women for planned a priori, sex-specific analyses. Initial models were adjusted for age and sex, followed by additional adjustment for diabetes mellitus, depression (10-item Center for Epidemiologic Studies-Depression scale score  $\geq 8$ ), body mass index, statin use, smoking, dyslipidemia, ethnicity, education, and living situation. Analyses were repeated similarly for

incident cognitive decline. To minimize immortal time bias during the period used to estimate BPV,<sup>33</sup> participants with incident dementia or cognitive decline in the first 2 years were excluded from the analysis. The study design is shown in Figure S1.

We investigated potential effect modification by sex, and antihypertensive drug use,<sup>3,34</sup> by including a multiplicative interaction term in the models. When significance was found, BPV tertiles were redefined separately within the subgroups and stratified analyses performed. Sensitivity analyses were also conducted restricting the analysis to only those participants who remained consistently on or off antihypertensive drugs during the BPV estimation period, to account for potential variability in BP that could be linked to initiation or discontinuation of antihypertensives.<sup>35</sup> A 2-sided *P* value of <0.05 was used as the cutoff for statistical significance. All analyses were conducted using Stata version 16 (StataCorp, College Station, TX).


## RESULTS

Among 19 114 individuals originally randomized into ASPREE, 16 758 participants remained in the study and had mean BP recorded at baseline, year 1, and year 2 visits, for estimation of BPV (Figure 1). Of these participants, 16 600 were free of dementia at 2 years, and 396 cases of incident dementia subsequently occurred over a median follow-up of 2.7 years (95% CI, 1.6–3.6). At 2 years, 14 105 participants were free of

cognitive decline, and 1993 events subsequently occurred over a median follow-up of 2.0 years (95% CI, 1.0–3.0). In the initial age and sex-adjusted Cox models, being in the highest tertile of BPV compared with the lowest tertile was associated with an increased risk of both incident dementia (HR, 1.33; 95% CI, 1.05–1.70) and cognitive decline (HR, 1.21; 95% CI, 1.09–1.35) (Figure S2). However, there was evidence that sex modified this association (interaction *P*=0.02 for incident dementia and *P*=0.15 for cognitive decline). As such, all subsequent analyses are presented separately for men and women.

Table 1 shows the baseline characteristics according to tertiles of BPV of the men and women included in the analysis of incident dementia. On average, women had higher BPV than men. As tertiles progressed from lowest to highest, mean age increased as did baseline and average systolic BP, and participants had more comorbidities such as diabetes mellitus, chronic kidney disease, and pack years of smoking. Baseline cognitive scores were similar across all BPV tertiles for both men and women. Characteristics of participants included in the analysis of incident cognitive decline demonstrated mostly similar patterns (Table S1).

Following the year 2 visit, incident dementia occurred in 2.6% (188/7318) of men and 2.2% (208/9282) of women, whereas incident cognitive decline occurred in 14.7% (915/6204) and 13.6% (1078/7901) of men and women, respectively (Figure 2). In the multivariate-adjusted Cox model, men in the highest tertile of BPV



**Figure 1. Consort flow diagram of participants included in the analysis.**

ASPREE indicates Aspirin in Reducing Events in the Elderly; BP, blood pressure; and BPV, blood pressure variability.

**Table 1. Baseline Characteristics of ASPREE Participants Included in the Dementia Incidence Analysis, by Sex and Tertiles of BPV (n=16 600)**

Characteristic	Men			Women		
	T1, n=2503	T2, n=2401	T3, n=2414	T1, n=3117	T2, n=3083	T3, n=3082
SD of SBP, mean (SD)	4.2 (1.6)	9.0 (1.4)	16.6 (4.4)	4.4 (1.7)	9.4 (1.4)	17.4 (5.0)
Baseline SBP, mm Hg, mean (SD)	137.9 (13.8)	140.5 (14.8)	145.0 (17.8)	133.6 (14.5)	136.4 (15.6)	142.6 (18.7)
Baseline diastolic blood pressure, mm Hg, mean (SD)	77.2 (8.9)	77.9 (9.3)	79.2 (10.3)	75.3 (9.5)	76.3 (9.8)	78.2 (11.0)
Baseline antihypertensive medications, n (%)	1116 (44.6)	1090 (45.4)	1360 (56.3)	1509 (48.4)	1665 (54.0)	1887 (61.2)
Average SBP* over blood pressure variability period, mean (SD)	137.7 (13.4)	139.4 (13.1)	141.9 (13.0)	133.3 (14.0)	135.6 (13.6)	139.7 (13.5)
Ethno-racial group, n (%)						
Australian White	2240 (89.5)	2152 (89.6)	2141 (88.7)	2666 (85.5)	2616 (84.9)	2592 (84.1)
US White	114 (4.6)	101 (4.2)	87 (3.6)	204 (6.5)	225 (7.3)	208 (6.8)
Black	69 (2.8)	65 (2.7)	71 (2.9)	131 (4.2)	143 (4.6)	169 (5.5)
Hispanic/Latino	52 (2.1)	43 (1.8)	61 (2.5)	82 (2.6)	67 (2.2)	70 (2.3)
Other	28 (1.1)	40 (1.7)	54 (2.2)	34 (1.1)	32 (1.0)	43 (1.4)
Age, y, n (%)						
65–73	1366 (54.6)	1263 (52.6)	1175 (48.7)	1701 (54.6)	1540 (50.0)	1392 (45.2)
≥74	1137 (45.4)	1138 (47.4)	1239 (51.3)	1416 (45.4)	1543 (50.1)	1690 (54.8)
Education y, n (%)						
<12	1096 (43.8)	1034 (43.1)	1038 (43.0)	1460 (46.8)	1385 (44.9)	1433 (46.5)
12–15	657 (26.3)	657 (27.4)	671 (27.8)	899 (28.8)	967 (31.4)	922 (29.9)
16+	750 (30.0)	710 (29.6)	705 (29.2)	758 (24.3)	731 (23.7)	727 (23.6)
Alcohol, n (%)						
Current	2096 (83.7)	2044 (85.1)	2013 (83.4)	2264 (72.6)	2229 (72.3)	2226 (72.2)
Former	173 (6.9)	153 (6.4)	167 (6.9)	150 (4.8)	122 (4.0)	150 (4.9)
Never	234 (9.4)	204 (8.5)	234 (9.7)	703 (22.6)	732 (23.7)	706 (22.9)
Body mass index, kg/m <sup>2</sup> , mean (SD)	27.9 (3.9)	27.9 (3.9)	28.1 (4.0)	28.1 (5.0)	28.1 (5.2)	28.4 (5.3)
Living alone, n (%)	482 (19.3)	456 (19.0)	519 (21.5)	1246 (40.0)	1275 (41.4)	1323 (42.9)
Current or past smoker, n (%)	1372 (54.8)	1330 (55.4)	1415 (58.6)	1080 (34.7)	1040 (33.7)	1067 (34.6)
Smoking pack years, mean (SD)	24.3 (27.7)	24.5 (25.5)	25.2 (25.4)	17.7 (20.2)	18.0 (18.9)	18.8 (21.5)
Diabetes mellitus, n (%)	265 (10.6)	291 (12.1)	331 (13.7)	270 (8.7)	246 (8.0)	304 (9.9)
Depression, n (%)	181 (7.2)	176 (7.3)	181 (7.5)	358 (11.5)	320 (10.4)	348 (11.3)
Dyslipidemia, n (%)	1392 (55.6)	1328 (55.3)	1326 (54.9)	2275 (73.0)	2233 (72.4)	2282 (74.0)
Chronic kidney disease, n (%)	507 (21.9)	545 (24.4)	643 (28.6)	702 (24.1)	704 (24.5)	878 (30.6)
Statin medications, n (%)	712 (28.5)	663 (27.6)	675 (28.0)	1025 (32.9)	1010 (32.8)	1084 (35.2)
Aspirin treatment assignment, n (%)	1249 (49.9)	1186 (49.4)	1189 (49.3)	1572 (50.4)	1516 (49.2)	1523 (49.4)
Pulse pressure, mean (SD)	60.7 (12.1)	62.6 (12.4)	65.9 (14.3)	58.2 (12.9)	60.1 (13.6)	64.3 (15.2)
Heart rate, mean (SD)	69.2 (10.4)	69.0 (11.0)	68.5 (11.1)	72.6 (9.9)	72.0 (10.2)	71.2 (10.6)
SD of heart rate variability, mean (SD)	5.4 (3.5)	5.7 (3.9)	6.2 (4.2)	5.0 (3.4)	5.3 (3.6)	5.7 (3.8)
Cognitive performance						
Modified Mini-Mental State Examination, mean (SD)	93.2 (4.5)	92.8 (4.7)	92.9 (4.6)	94.3 (4.3)	94.2 (4.2)	94.2 (4.3)
Hopkins Verbal Learning Test-Revised delayed recall, mean (SD)	7.3 (2.8)	7.3 (2.9)	7.3 (2.8)	8.3 (2.7)	8.4 (2.7)	8.3 (2.7)

(Continued)

were at significantly increased risk of both incident dementia (HR, 1.68; 95% CI, 1.19–2.39;  $P=0.004$ ) and cognitive decline (HR, 1.36; 95% CI, 1.16–1.59;  $P<0.0001$ ) compared with those in the lowest tertile (Table 2). The

HRs were minimally changed after further adjustment for additional covariates including ethnicity, living status, smoking, dyslipidemia, or chronic kidney disease. Furthermore, these associations remained consistent

**Table 1. Continued**


Characteristic	Men			Women		
	T1, n=2503	T2, n=2401	T3, n=2414	T1, n=3117	T2, n=3083	T3, n=3082
Symbol Digit Modalities Test, mean (SD)	36.4 (9.6)	35.9 (9.9)	35.1 (9.9)	38.8 (9.8)	38.7 (10.0)	37.6 (10.1)
Controlled Oral Word Association Test, mean (SD)	11.7 (4.5)	11.5 (4.5)	11.6 (4.5)	12.6 (4.6)	12.7 (4.5)	12.7 (4.5)

Age was categorized based on the median age of participants, which was 74 years. Ethno-racial group was based on self-report. Other ethno-racial group was defined as any category with less than 200 participants overall, which included Aboriginal or Torres Strait Islander, Native American, multiple races or ethnic groups, Native Hawaiian or Pacific Islander, and those who indicated that they were not Hispanic but did not state another race or ethnic group. Diabetes mellitus was defined as a participants' report of diabetes mellitus or a fasting glucose level of  $\geq 126$  mg per deciliter ( $\geq 7$  mmol per liter) or receipt of treatment for diabetes mellitus. Depression was defined as a 10-item Center for Epidemiological Studies Depression Scale score of  $\geq 8$ . Dyslipidemia was defined as serum cholesterol level of  $\geq 212$  mg per deciliter ( $\geq 5.5$  mmol per liter) in Australia and  $\geq 240$  mg per deciliter ( $\geq 6.2$  mmol per liter) in the United States or as a low-density lipoprotein level of  $>160$  mg per deciliter ( $>4.1$  mmol per liter); or taking cholesterol-lowering medication. Chronic kidney disease was defined as estimated glomerular filtration rate  $<60$  mL/min per  $1.73$  m<sup>2</sup> or albumin to creatinine ratio  $\geq 3$  mg/mmol. ASPREE indicates Aspirin in Reducing Events in the Elderly; BPV, blood pressure variability; SBP, systolic blood pressure; and T, tertile.

\*Over the period in which BPV was measured, thus baseline to the second annual visit.

after exclusion of men with a stroke or myocardial infarction during the trial (data not shown). In women, there was no significant association between tertile of BPV and incident dementia (HR, 1.01; 95% CI, 0.72–1.42;  $P=0.96$ ) or cognitive decline (HR, 1.14; 95% CI, 0.98–1.32;  $P=0.09$ ). When BPV was treated as a continuous variable, the findings in men and women remained consistent (Table 2).

In sensitivity analysis limiting the cohort to individuals who remained consistently on or off antihypertensive drugs throughout the period when BPV was estimated, an additional 729 men and 752 women from the analysis of incident dementia, and 617 men and 648 women from the analysis of cognitive decline, were excluded. The results, however, remained consistent with the main findings, showing an increased



**Figure 2. Cumulative incidence of events according to blood pressure variability tertile; dementia incidence in men (A); dementia incidence in women (B); incidence of cognitive decline in men (C); and incidence of cognitive decline in women (D). BPV indicates blood pressure variability; and T, tertile.**

**Table 2. Cox Proportional Hazards Analysis for the Association Between BPV and Incident Dementia and Cognitive Decline**

	No.	No. of Events	Age Adjusted			Multivariate Adjusted*		
			HR	95% CI	P Value	HR	95% CI	P Value
Dementia								
Men	7318	188						
BPV (continuous)			1.33	1.12–1.60	0.002	1.33	1.11–1.60	0.002
BPV tertile								
Tertile 1	2503	51	Reference			Reference		
Tertile 2	2401	48	0.94	0.64–1.40	0.77	0.96	0.65–1.43	0.84
Tertile 3	2414	89	1.68	1.19–2.38	0.003	1.68	1.19–2.39	0.004
Women	9282	208						
BPV (continuous)			1.00	0.85–1.19	0.96	1.00	0.85–1.19	0.98
BPV tertile								
Tertile 1	3117	60	Reference			Reference		
Tertile 2	3083	73	1.03	0.73–1.44	0.88	1.03	0.74–1.45	0.85
Tertile 3	3082	75	1.01	0.72–1.41	0.96	1.01	0.72–1.42	0.96
Cognitive decline								
Men	6204	915						
BPV (continuous)			1.02	1.00–1.03	0.007	1.02	1.01–1.03	0.005
BPV tertile								
Tertile 1	2107	305	Reference			Reference		
Tertile 2	2043	258	0.99	0.84–1.17	0.92	1.00	0.85–1.19	0.97
Tertile 3	2054	352	1.34	1.14–1.56	<0.0001	1.36	1.16–1.59	<0.0001
Women	7901	1078						
BPV (continuous)			1.01	1.00–1.02	0.06	1.01	1.00–1.02	0.10
BPV tertile								
Tertile 1	2672	336	Reference			Reference		
Tertile 2	2608	327	0.98	0.84–1.14	0.76	0.98	0.84–1.14	0.81
Tertile 3	2621	415	1.15	0.99–1.32	0.07	1.14	0.98–1.32	0.09

BPV indicates blood pressure variability; and HR, hazard ratio.

\*Adjusted for age, average systolic blood pressure, antihypertensive medications at baseline, education, diabetes mellitus, depression, body mass index, and statin medications.

risk of incident dementia and cognitive decline for men in the highest tertile of BPV compared with the lowest tertile but not in women (Table S2).

We further explored the relationship between use of antihypertensive drugs and the cognitive end points. In men but not women, there was a significant interaction between antihypertensive use and BPV for both incident dementia ( $P=0.01$ ) and cognitive decline ( $P=0.02$ ). Men in the highest tertile who were not on antihypertensive drugs during the BPV estimation period were not at increased risk of dementia (HR, 0.83; 95% CI, 0.48–1.43;  $P=0.51$ ), whereas men in the middle and highest tertiles who were consistently on antihypertensive drugs were at increased risk (T2: HR, 2.11; 95% CI, 1.14–3.91;  $P=0.02$ ; T3: HR, 2.97; 95% CI, 1.65–5.34;  $P<0.001$ ) (Table 3). Likewise, men using antihypertensives in the highest tertile had an increased risk of cognitive decline relative to those in the lowest tertile (HR, 1.68; 95% CI, 1.34–2.12;

$P<0.001$ ), but no such association was seen for the second tertile. Treating BPV as a continuous variable resulted in similar findings.

In sensitivity analyses using alternate BPV indices, the observed relationships were consistent with our primary analysis (Table S3). Further sensitivity analysis using BPV calculated from 4 measurements (baseline, year 1, 2, and 3 visits) and restricting to events that occurred after the year 3 visit, produced similar results for dementia in men, but cognitive decline was no longer significant (Table S4). For comparative purposes we also examined the association between other BP measures and incident dementia and cognitive decline in the cohort. The results indicated that none of the measures—systolic or diastolic BP, high BP, or use of antihypertensive drug—were associated with either dementia or cognitive decline in men or women (Table S5). Lastly, we did not observe any significant

**Table 3. Cumulative Incidence of Dementia and Cognitive Decline According to BPV in Men, Stratified by Antihypertensive Medication Use Over the BPV Assessed Period**

	No.	No Antihypertensive Medication				No.	Consistent Antihypertensive Medication			
		No. of Events	HR*	95% CI	P Value		No. of Events	HR*	95% CI	P Value
Dementia	3111	70				3478	92			
BPV (continuous)			0.97	0.93–1.02	0.29			1.06	1.03–1.09	<0.0001
BPV tertile										
Tertile 1	1055	28	Ref.			1178	15	Ref.		
Tertile 2	1019	16	0.58	0.31–1.08	0.09	1146	31	2.11	1.14–3.91	0.02
Tertile 3	1037	26	0.83	0.48–1.43	0.51	1154	46	2.97	1.65–5.34	<0.0001
Cognitive decline	2665	377				2922	439			
BPV (continuous)			0.99	0.97–1.01	0.44			1.02	1.01–1.04	0.002
BPV tertile										
Tertile 1	906	128	Ref.			992	124	Ref.		
Tertile 2	875	120	1.03	0.80–1.32	0.84	959	125	1.05	0.82–1.35	0.71
Tertile 3	884	129	1.02	0.79–1.30	0.89	971	190	1.68	1.34–2.12	<0.0001

BPV indicates blood pressure variability; and HR, hazard ratio.

\*Adjusted for age, average systolic blood pressure, education, diabetes mellitus, depression, body mass index, and statin medications.

association between diastolic BPV and incident dementia or cognitive decline (Table S6).

## DISCUSSION

In this post hoc analysis of ASPREE participants without dementia, those in the highest tertile of BPV compared with the lowest were at significantly increased risk of incident dementia and cognitive decline during follow-up, independent of mean systolic BP. Sex and use of antihypertensive drugs modified this association, whereby the risk of incident dementia and cognitive decline appeared greatest in men who were receiving antihypertensive treatment. These findings remained consistent in sensitivity analyses, which included restricting the cohort to those without change in antihypertensive drug use during the BPV estimation period and use of alternate estimates of BPV.

Our findings support previous work establishing BPV as an independent risk factor for cognitive impairment.<sup>8–15,36</sup> However, our work expands this understanding to older, relatively healthy adults (including those without hypertension) who had reached late life without significant cognitive impairment; a group that is not typically considered at high risk for dementia in their remaining lifespan. Furthermore, our results also provide the first evidence of possible sex-specific effects of BPV on cognition. Although we and others have found that women have higher BPV than men,<sup>37,38</sup> to our knowledge, none considered whether the association between BPV and cognitive impairment differs between men and women.

The pathobiological mechanisms connecting increased BPV with cognitive decline and dementia have not been fully established. Accumulating evidence suggests BPV is associated with structural brain changes, including increased white matter hyperintensities, cerebral microbleeds, and enlarged perivascular spaces.<sup>39–42</sup> The basal forebrain cholinergic neuronal degeneration and associated presynaptic cholinergic denervation in Alzheimer's disease may influence sympathetic and parasympathetic autoregulation of BP, contributing to BPV. The resultant hemodynamic instability can increase shear stress and promote microvascular damage, which may affect permeability of the blood brain barrier and accelerate neuronal injury.<sup>43</sup> Although all ASPREE participants were without major cognitive deficits at baseline, we cannot exclude the possibility that subclinical disease was present and contributed via this pathway.

We considered several explanations for why men, but not women, were at increased risk for dementia and cognitive impairment in our analysis. It may reflect higher cumulative burden from traditional midlife vascular risk factors that are the strongest risk for late-life dementia. These include BP<sup>4,43</sup> and smoking,<sup>44</sup> and men in our study did have higher exposures to both, yet our findings persisted after adjustment for these covariates. Increased vascular stiffness is associated with cognitive decline,<sup>45</sup> and stroke and myocardial infarction are manifestations of the underlying vascular risk burden. However, we observed similar pulse pressures in men and women, and our associations remained consistent after exclusion of men with a stroke or myocardial infarction during the trial.



The possibility of different underlying pathways for cognitive decline in men and women exists, perhaps based partly on timing of risk factor exposure, as sex-specific associations with late-life cognition have been previously reported.<sup>46,47</sup> Furthermore, the cerebrovasculature is affected by sex hormones, which may lead to differences in how cerebral blood vessels function under both physiological and pathological conditions.<sup>48</sup> The effect of estrogen exposure, either through longer endogenous estrogen exposure or hormone therapy, is one such possibility. Although hormone therapy did not benefit cognition in the Women's Health Initiative,<sup>49</sup> other research suggests that longer endogenous estrogen exposure and hormone therapy are associated with higher cognitive status in late life.<sup>50,51</sup> The age of women in ASPREE would suggest that many went through menopause at a time when hormone therapy was more widespread, and it is possible they had higher lifetime estrogen exposure.

We observed that the association between high BPV and cognitive decline and dementia was strongest in men who reported using antihypertensive drugs during the 2 years in which BPV was assessed. Some possibilities to explain this finding include that antihypertensive use may be a proxy for underlying vascular risk, and men in our cohort could have had longer durations of hypertension or were more poorly controlled. Indeed, it has been shown that intensive blood pressure control with antihypertensives reduces the risk of mild cognitive impairment.<sup>52</sup> Poor adherence to antihypertensives influences visit-to-visit BPV,<sup>35</sup> and men in our cohort could have been less adherent to their treatments. Although we cannot offer a definitive explanation for the sex-based differences, our results should not be interpreted as to suggest that antihypertensive treatment in men is harmful to their cognitive trajectory. Sex is clearly emerging as a key biological variable in cerebrovascular and cardiovascular research.<sup>48,53</sup> Our findings highlight the need for more research investigating the potential mechanisms underlying sex-specific differences in diseases of aging and further support the consideration of potential sex-related differences in clinical practice and in the design of future trials.

### Strengths and Limitations

The large sample size, administration of a comprehensive cognitive battery at multiple study visits, standardized BP assessments, and adjudicated dementia diagnoses are key strengths of our study. The cohort's inclusion of individuals with and without hypertension expands its generalizability to older adults not receiving interventions such as aggressive BP lowering that may affect the underlying causal pathway for dementia.<sup>52</sup> In contrast to

previous studies,<sup>36</sup> we chose a more conservative analysis by only considering cognitive decline and dementia end points occurring after the period during which BPV was estimated. Although minimizing immortal time bias, this approach potentially reduces the precision around effect size estimates because it excludes events occurring early in the study. We also conducted multiple sensitivity analyses that further supported the results. Finally, the lack of significant association of the cognitive end points with any of the other traditional BP measures adds further strength to the concept of BPV as an independent risk factor for cognitive decline and dementia.

Our study has important limitations we acknowledge. It is a post hoc analysis whose findings can be subject to unmeasured confounders. We were unable to account for adjustments to antihypertensive regimens or nonadherence, although our sensitivity analyses limiting the cohort to those consistently on or off antihypertensives during the BPV estimation period did not alter the findings. Reverse causation is also a possibility, because greater BPV may stem from dysfunctional autoregulation of BP in those with cortical atrophy, and we cannot exclude the possibility that subclinical disease was present at baseline in some individuals. The sex-related differences observed could reflect inadequate statistical power, as fewer women experienced dementia or cognitive impairment during the follow-up period. We were unable to account for lifetime estrogen exposure, which may have influenced the sex-related differences observed.<sup>50</sup> Finally, our findings are associative, and only a well-designed prospective intervention trial can establish whether high BPV is a viable therapeutic target to lower the risk of cognitive decline and dementia.

## CONCLUSIONS

In adults who have reached older ages free of evidence of dementia or major cognitive impairment, high BPV was independently associated with increased risk of dementia and cognitive decline, particularly in men. Future research should investigate sex-specific effects of high BPV on cognition and prospectively test whether reducing BPV preserves late-life cognitive function.

### ARTICLE INFORMATION

Received October 1, 2020; accepted March 24, 2021.

#### Affiliations

Department of Pharmacy Practice and Science, College of Pharmacy (M.E.E.); and Department of Family Medicine, Carver College of Medicine

(M.E.E.), The University of Iowa, Iowa City, IA; School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia (J.R., E.K.C., C.M.R., R.L.W., S.G.O., R.W., E.S., A.M.T., J.J.M.); School of Public Health, Curtin University, Perth, Western Australia, Australia (E.K.C., C.M.R.); HealthPartners Institute, Minneapolis, MN (K.L.M.); Medical School, Royal Perth Hospital, University of Western Australia, Perth, Western Australia, Australia (L.J.B.); Menzies Institute for Medical Research, University of Tasmania, Hobart, Tasmania, Australia (M.R.N.); Department of Family Medicine (R.C.S.); and Rush Alzheimer's Disease Center (R.C.S.), Rush University Medical Center, Chicago, IL; Florey Institute of Neuroscience and Mental Health, Melbourne, Victoria, Australia (A.B.); Berman Center for Outcomes and Clinical Research, Hennepin-Health Research Institute, Hennepin Healthcare, Minneapolis, MN (A.M.M.); and Division of Geriatrics, Department of Medicine, Hennepin Healthcare, Minneapolis, MN (A.M.M.).

### Acknowledgments

A. G. Bayer provided aspirin and matching placebo for ASPREE but had no other role in the study.

### Sources of Funding

The ASPREE trial was supported by grants (U01AG029824 and U19AG062682) from the National Institute on Aging and the National Cancer Institute at the National Institutes of Health, by grants (334047 and 1127060) from the National Health and Medical Research Council of Australia, and by Monash University and the Victorian Cancer Agency.

### Disclosures

None.

### Supplementary Material

Tables S1–S6

Figures S1–S2

## REFERENCES

- United Nations, Department of Economic and Social Affairs, Population Division. World Population Ageing 2017—Highlights (ST/ESA/SER.A/397). 2017.
- Gottesman RF, Schneider ALC, Albert M, Alonso A, Bandeen-Roche K, Coker L, Coresh J, Knopman D, Power MC, Rawlings A, et al. Midlife hypertension and 20-year cognitive change: the Atherosclerosis Risk in Communities Neurocognitive Study. *JAMA Neurol*. 2014;71:1218–1227. DOI: 10.1001/jamaneurol.2014.1646.
- Ou YN, Tan CC, Shen XN, Xu W, Hou XH, Dong Q, Tan L, Yu JT. Blood pressure and risks of cognitive impairment and dementia: a systematic review and meta-analysis of 209 prospective studies. *Hypertension*. 2020;76:217–225. DOI: 10.1161/HYPERTENSIONAHA.120.14993.
- Walker KA, Sharrett AR, Wu A, Schneider ALC, Albert M, Lutsey PL, Bandeen-Roche K, Coresh J, Gross AL, Windham BG, et al. Association of midline to late-life blood pressure patterns with incident dementia. *JAMA*. 2019;322:535–545.
- Abell JG, Kivimäki M, Dugravot A, Tabak AG, Fayosse A, Shipley M, Sabia S, Singh-Manoux A. Association between systolic blood pressure and dementia in the Whitehall II cohort study: role of age, duration, and threshold used to define hypertension. *Eur Heart J*. 2018;39:3119–3125. DOI: 10.1093/eurheartj/ehy288.
- Levine DA, Galecki AT, Langa KM, Unverzagt FW, Kabeto MU, Giordani B, Cushman M, McClure LA, Safford MM, Wadley VG. Blood pressure and cognitive decline over 8 years in middle-aged and older black and white Americans. *Hypertension*. 2019;73:310–318. DOI: 10.1161/HYPERTENSIONAHA.118.12062.
- Rouch L, Cestac P, Hanon O, Ruidavets J-B, Ehlinger V, Gentil C, Cool C, Helmer C, Dartigues J-F, Bouhanick B, et al. Blood pressure and cognitive performances in middle-aged adults: the aging, health and work longitudinal study. *J Hypertens*. 2019;37:1244–1253. DOI: 10.1097/HJH.0000000000002013.
- Oishi E, Ohara T, Sakata S, Fukuhara M, Hata J, Yoshida D, Shibata M, Ohtsubo T, Kitazono T, Kiyohara Y, et al. Day-to-day blood pressure variability and risk of dementia in a general Japanese elderly population. *Circulation*. 2017;136:516–525. DOI: 10.1161/CIRCULATIONAHA.116.025667.
- Zhou TL, Kroon AA, van Sloten TT, van Boxtel MPJ, Verhey FRJ, Schram MT, Köhler S, Stehouwer CDA, Henry RMA. Greater blood pressure variability is associated with lower cognitive performance. *Hypertension*. 2019;73:803–811. DOI: 10.1161/HYPERTENSIONAHA.118.12305.
- Yoo JE, Shin DW, Han K, Kim D, Lee SP, Jeong SM, Lee J, Kim S. Blood pressure variability and the risk of dementia. *Hypertension*. 2020;75:982–990. DOI: 10.1161/HYPERTENSIONAHA.119.14033.
- Qin B, Viera AJ, Muntner P, Plassman BL, Edwards LJ, Adair LS, Popkin BM, Mendez MA. Visit-to-visit variability in blood pressure is related to late-life cognitive decline. *Hypertension*. 2016;68:106–113. DOI: 10.1161/HYPERTENSIONAHA.116.07494.
- Nagai M, Hoshida S, Ishikawa J, Shimada K, Kario K. Visit-to-visit blood pressure variations: new independent determinants for cognitive function in the elderly at high risk of cardiovascular disease. *J Hypertens*. 2012;30:1556–1563. DOI: 10.1097/HJH.0b013e3283552735.
- Sabayan B, Wijsman LW, Foster-Dingley JC, Stott DJ, Ford I, Buckley BM, Sattar N, Jukema JW, van Osch MJP, van der Grond J, et al. Association of visit-to-visit variability in blood pressure with cognitive function in old age: prospective cohort study. *BMJ*. 2013;347:f4600. DOI: 10.1136/bmj.f4600.
- Böhm M, Schumacher H, Leong D, Mancina G, Unger T, Schmieder R, Custodis F, Diener H-C, Laufs U, Lonn E, et al. Systolic blood pressure variation and mean heart rate is associated with cognitive dysfunction in patients with high cardiovascular risk. *Hypertension*. 2015;65:651–661. DOI: 10.1161/HYPERTENSIONAHA.114.04568.
- Epstein NU, Lane KA, Farlow MR, Risacher SL, Saykin AJ, Gao S; Alzheimer's Disease Neuroimaging Initiative. Cognitive dysfunction and greater visit-to-visit systolic blood pressure variability. *J Am Geriatr Soc*. 2013;61:2168–2173. DOI: 10.1111/jgs.12542.
- de Heus RAA, Olde Rikkert MGM, Tully PJ, Lawlor BA, Classen JAHR; NILVAD Study Group. Blood pressure variability and progression of clinical Alzheimer disease. *Hypertension*. 2019;74:1172–1180. DOI: 10.1161/HYPERTENSIONAHA.119.13664.
- Kronish IM, Kent S, Moise N, Shimbo D, Safford MM, Kynard RE, O'Beirne R, Sullivan A, Muntner P. Barriers to conducting ambulatory and home blood pressure monitoring during hypertension screening in the United States. *J Am Soc Hypertens*. 2017;11:573–580. DOI: 10.1016/j.jash.2017.06.012.
- Parati G, Stergiou GS, Dolan E, Bilo G. Blood pressure variability: clinical relevance and application. *J Clin Hypertens*. 2018;20:1133–1137. DOI: 10.1111/jch.13304.
- Nelson MR; ASPREE Investigator Group. Study design of ASPirin in Reducing Events in the Elderly (ASPREE): a randomized, controlled trial. *Contemp Clin Trials*. 2013;36:555–564. DOI: 10.1016/j.cct.2013.09.014.
- McNeil JJ, Woods RL, Nelson MR, Murray AM, Reid CM, Kirpach B, Storey E, Shah RC, Wolfe RS, Tonkin AM, et al. Baseline characteristics of participants in the ASPREE (ASPirin in Reducing Events in the Elderly) study. *J Gerontol A Biol Sci Med Sci*. 2017;72:1586–1593. DOI: 10.1093/gerona/glw342.
- McNeil JJ, Woods RL, Nelson MR, Reid CM, Kirpach B, Wolfe R, Storey E, Shah RC, Lockery JE, Tonkin AM, et al. Effect of aspirin on disability-free survival in the healthy elderly. *N Engl J Med*. 2018;379:1499–1508. DOI: 10.1056/NEJMoa1800722.
- Ryan J, Storey E, Murray AM, Woods RL, Wolfe R, Reid CM, Nelson MR, Chong TTJ, Williamson JD, Ward SA, et al. Randomized placebo-controlled trial of the effects of aspirin on dementia and cognitive decline. *Neurology*. 2020;95:e320–e331. DOI: 10.1212/WNL.0000000000009277.
- Ryan J, Woods RL, Britt C, Murray AM, Shah RC, Reid CM, Kirpach B, Wolfe RS, Nelson MR, Lockery JE, et al. Normative performance of healthy older individuals on the Modified Mini-Mental State (3MS) examination according to ethno-racial group, gender, age, and education level. *Clin Neuropsychol*. 2018;33:779–797. DOI: 10.1080/13854046.2018.1488996.
- Benedict RHB, Schretlen D, Groninger L, Brandt J. Hopkins Verbal Learning Test—Revised: normative data and analysis of inter-form and test-retest reliability. *Clin Neuropsychol*. 2001;12:43–55. DOI: 10.1076/clin.12.1.43.1726.
- Ross TP. The reliability of cluster and switch scores for the Controlled Oral Word Association Test. *Arch Clin Neuropsychol*. 2003;18:153–164. DOI: 10.1093/arclin/18.2.153.

26. Smith A. *Symbol Digit Modalities Test (SDMT) Manual (Revised)*. Los Angeles: Western Psychological Services; 1982.
27. Pickering TG, Hall JE, Appel LJ, Falkner B, Graves J, Hill MN, Jones DW, Kurtz T, Sheps SG, Roccella EJ; Subcommittee of Professional and Public Education of the American Heart Association on High Blood Pressure Research. Recommendations for blood pressure measurement in humans and experimental animals, part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. *Hypertension*. 2005;45:142–161. DOI: 10.1161/01.HYP.0000150859.47929.8e.
28. Graham DP, Cully JA, Snow AL, Massman P, Doody R. The Alzheimer's Disease Assessment Scale-Cognitive subscale: normative data for older adult controls. *Alzheimer Dis Assoc Disord*. 2004;18:236–240.
29. D'Elia L. *Color Trails Test: Professional Manual*. Odessa, FL: Psychological Assessment Resources; 1996.
30. Alegret M, Boada-Rovira M, Vinyes-Junqué G, Valero S, Espinosa A, Hernández I, Modinos G, Rosende-Roca M, Mauleón A, Becker JT, et al. Detection of visuo-perceptual deficits in preclinical and mild Alzheimer's disease. *J Clin Exp Neuropsychol*. 2009;31:860–867. DOI: 10.1080/13803390802595568.
31. Fish J. Alzheimer's disease cooperative study ADL scale. In: Kreutzer JS, DeLuca J, Caplan B, eds. *Encyclopedia of Clinical Neuropsychology*. New York, NY: Springer; 2011. DOI: 10.1007/978-0-387-79948-3\_1791.
32. American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)*. Washington, DC: American Psychiatric Association; 1994.
33. Lévesque LE, Hanley JA, Kezouh A, Suissa S. Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes. *BMJ*. 2010;e340:b5087. DOI: 10.1136/bmj.b5087.
34. Wijsman LW, de Craen AJM, Muller M, Sabayan B, Stott D, Ford I, Trompet S, Jukema JW, Westendorp RGJ, Mooijaart SP. Blood pressure lowering medication, visit-to-visit blood pressure variability, and cognitive function in older age. *Am J Hypertens*. 2016;29:311–318.
35. Kronish IM, Lynch AJ, Oparil S, Whittle J, Davis BR, Simpson LM, Krousel-Wood M, Cushman WC, Chang TI, Muntner P. The association between antihypertensive medication nonadherence and visit-to-visit variability of blood pressure. Findings from the Antihypertensive and Lipid-Lowering to Prevent Heart Attack Trial. *Hypertension*. 2016;68:39–45. DOI: 10.1161/HYPERTENSIONAHA.115.06960.
36. Rouch L, Cestac P, Sallerin B, Piccoli M, Benattar-Zibi L, Bertin P, Berrut G, Corruble E, Derumeaux G, Falissard B, et al. Visit-to-visit blood pressure variability is associated with cognitive decline and incident dementia. *Hypertension*. 2020;76:1280–1288. DOI: 10.1161/HYPERTENSIONAHA.119.14553.
37. Rothwell PM, Howard SC, Dolan E, O'Brien E, Dobson J, Dahlöf B, Sever PS, Poulter NR. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. *Lancet*. 2010;375:895–905. DOI: 10.1016/S0140-6736(10)60308-X.
38. Muntner P, Shimbo D, Tonelli M, Reynolds K, Arnett DK, Oparil S. The relationship between visit-to-visit variability in systolic blood pressure and all-cause mortality in the general population: findings from NHANES III, 1988 to 1994. *Hypertension*. 2011;57:160–166. DOI: 10.1161/HYPERTENSIONAHA.110.162255.
39. Tully PJ, Yano Y, Launer LJ, Kario K, Nagai M, Mooijaart SP, Claassen JAHR, Lattanzi S, Vincent AD, Tzourio C, et al. Variability in Blood Pressure and Brain Health Consortium. Association between blood pressure variability and cerebral small-vessel disease: a systematic review and meta-analysis. *J Am Heart Assoc*. 2020;9:e013841. DOI: 10.1161/JAHA.119.013841.
40. Lattanzi S, Brigo F, Vernieri F, Silvestrini M. Visit-to-visit variability in blood pressure and Alzheimer's disease. *J Clin Hypertens*. 2018;20:918–924. DOI: 10.1111/jch.13290.
41. Ma Y, Yilmaz P, Bos D, Blacker D, Viswanathan A, Ikram MA, Hofman A, Vernooij MW, Ikram MK. Blood pressure variation and subclinical brain disease. *J Am Coll Cardiol*. 2020;75:2387–2399. DOI: 10.1016/j.jacc.2020.03.043.
42. de Heus RAA, Reumers SFI, van der Have A, Tumelaire M, Tulley PJ, Claassen JAHR. Day-to-day home blood pressure variability is associated with cerebral small vessel disease burden in a memory clinic population. *J Alzheimers Dis*. 2020;74:463–472. DOI: 10.3233/JAD-191134.
43. Walker KA, Power MC, Gottesman RF. Defining the relationship between hypertension, cognitive decline, and dementia: a review. *Curr Hypertens Rep*. 2017;19:24. DOI: 10.1007/s11906-017-0724-3.
44. Zhong G, Wang Y, Zhang Y, Guo JJ, Zhao Y. Smoking is associated with an increased risk of dementia: a meta-analysis of prospective cohort studies with investigation of potential effect modifiers. *PLoS One*. 2015;10:e0118333. DOI: 10.1371/journal.pone.0118333.
45. Li X, Lyu P, Ren Y, An J, Dong Y. Arterial stiffness and cognitive impairment. *J Neurol Sci*. 2017;380:1–10. DOI: 10.1016/j.jns.2017.06.018.
46. Altschul DM, Wraw C, Der G, Gale CR, Deary IJ. Hypertension development by midlife and the roles of premorbid cognitive function, sex, and their interaction. *Hypertension*. 2019;73:812–819. DOI: 10.1161/HYPERTENSIONAHA.118.12164.
47. Gilsanz P, Mayeda ER, Glymour MM, Quesenberry CP, Mungas DM, DeCarli C, Dean A, Whitmer RA. Female sex, early-onset hypertension, and risk of dementia. *Neurology*. 2017;89:1886–1893. DOI: 10.1212/WNL.0000000000004602.
48. Robison LS, Gannon OJ, Salinero AE, Zuloaga KL. Contributions of sex to cerebrovascular function and pathology. *Brain Res*. 2019;1710:43–60. DOI: 10.1016/j.brainres.2018.12.030.
49. Shumaker SA, Legault C, Rapp SR, Thal L, Wallace RB, Ockene JK, Hendrix SL, Jones BN III, Assaf AR, Jackson RD, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. *JAMA*. 2003;289:2651–2662. DOI: 10.1001/jama.289.20.2651.
50. Matyi JM, Rattinger GB, Schwartz S, Buhusi M, Tschanz JT. Lifetime estrogen exposure and cognition in late life: the Cache County Study. *Menopause*. 2019;26:1366–1374. DOI: 10.1097/GME.0000000000001405.
51. Ryan J, Carrière I, Scali J, Ritchie K, Ancelin M-L. Life-time estrogen exposure and cognitive functioning in later life. *Psychoneuroendocrinology*. 2009;34:287–298. DOI: 10.1016/j.psyneuen.2008.09.008.
52. The SPRINT MIND Investigators for the SPRINT Research Group. Effect of intensive vs standard blood pressure control on probable dementia: a randomized clinical trial. *JAMA*. 2019;321:553–561. DOI: 10.1001/jama.2018.21442.
53. Volgman AS, Bairey Merz CN, Aggarwal NT, Bittner V, Bunch TJ, Gorelick PB, Maki P, Patel HN, Poppas A, Ruskin J, et al. Sex differences in cardiovascular disease and cognitive impairment: another health disparity for women? *J Am Heart Assoc*. 2019;8:e013154. DOI: 10.1161/JAHA.119.013154.

# **SUPPLEMENTAL MATERIAL**

**Table S1. Baseline characteristics of ASPREE participants included in the cognitive decline analysis, by sex and tertiles of blood pressure variability (n=14,150).**

Characteristic	Men			Women		
	T1, n=2,107	T2, n=2,043	T3, n=2,054	T1, n=2,672	T2, n=2,608	T3, n=2,621
Standard deviation of systolic blood pressure, mean (SD)	4.3 (1.6)	9.0 (1.4)	16.5 (4.4)	4.4 (1.7)	9.4 (1.4)	17.4 (5.0)
Baseline systolic blood pressure, mmHg, mean (SD)	138.0 (14.0)	140.3 (14.8)	145.0 (17.7)	133.3 (14.6)	136.7 (15.8)	142.6 (18.7)
Baseline diastolic blood pressure, mmHg, mean (SD)	77.3 (9.0)	77.9 (9.3)	79.3 (10.3)	75.4 (9.5)	76.5 (9.8)	78.3 (11.1)
Baseline antihypertensive medications, n (%)	934 (44.3)	915 (44.8)	1144 (55.7)	1303 (48.8)	1410 (54.1)	1598 (61.0)
Average systolic blood pressure <sup>a</sup> over BPV period, mean (SD)	137.8 (13.6)	139.4 (13.1)	142.0 (12.9)	133.1 (14.1)	135.9 (13.8)	139.7 (13.5)
Ethno-racial group, n (%)						
Australian white	1889 (89.7)	1822 (89.2)	1834 (89.3)	2278 (85.3)	2234 (85.7)	2220 (84.7)
U.S. white	98 (4.7)	90 (4.4)	77 (3.8)	185 (6.9)	189 (7.3)	182 (6.9)
African-American	56 (2.7)	58 (2.8)	50 (2.4)	119 (4.5)	110 (4.2)	131 (5.0)
Hispanic/Latino	39 (1.9)	35 (1.7)	46 (2.2)	63 (2.4)	47 (1.8)	53 (2.0)
Other	25 (1.2)	38 (1.9)	47 (2.3)	27 (1.0)	28 (1.1)	35 (1.3)
Age, y, n (%)						
65-73	1132 (53.8)	1066 (52.2)	997 (48.5)	1460 (54.6)	1275 (48.9)	1170 (44.6)
≥ 74	975 (46.3)	977 (47.8)	1057 (51.5)	1212 (45.4)	1333 (51.1)	1451 (55.4)
Education y, n (%)						
<12	946 (44.9)	885 (43.3)	873 (42.5)	1269 (47.5)	1176 (45.1)	1220 (46.6)
12-15	540 (25.6)	565 (27.7)	566 (27.6)	773 (29.0)	814 (31.2)	777 (29.7)
16+	621 (29.5)	593 (29.0)	615 (29.9)	630 (23.6)	618 (23.7)	624 (23.8)
Alcohol, n (%)	1769 (84.0)	1732 (84.8)	1726 (84.0)	1969 (73.7)	1888 (72.4)	1901 (72.5)
Current	139 (6.6)	123 (6.0)	135 (6.6)	120 (4.5)	101 (3.9)	120 (4.6)
Former	199 (9.4)	188 (9.2)	193 (9.4)	583 (21.8)	619 (23.7)	600 (22.9)
Never						
Body Mass Index, kg/m <sup>2</sup> , mean (SD)	27.9 (3.8)	27.9 (3.9)	28.0 (3.9)	28.0 (5.0)	28.0 (5.2)	28.4 (5.3)
Living alone, n (%)	399 (18.9)	386 (19.0)	432 (21.0)	1052 (39.4)	1074 (41.2)	1123 (42.9)
Current or past smoker, n (%)	1152 (54.7)	1120 (54.8)	1208 (58.8)	895 (33.5)	861 (33.0)	909 (34.7)
Smoking Pack Years, mean (SD)	23.8 (27.3)	24.9 (25.8)	24.8 (25.8)	17.4 (20.1)	18.0 (19.1)	18.5 (19.3)
Diabetes, n (%)	223 (10.6)	249 (12.2)	270 (13.2)	224 (8.4)	194 (7.4)	238 (9.1)
Depression, n (%)	149 (7.1)	143 (7.0)	141 (6.9)	308 (11.5)	255 (9.8)	293 (11.2)
Dyslipidemia, n (%)	1180 (56.0)	1127 (55.2)	1126 (54.8)	1959 (73.3)	1892 (72.6)	1952 (74.5)
Chronic Kidney Disease, n (%)	441 (22.6)	464 (24.4)	547 (28.6)	601 (24.0)	602 (24.8)	744 (30.4)
Statin medications, n (%)	590 (28.0)	561 (27.5)	571 (27.8)	893 (33.4)	853 (32.7)	926 (35.3)
Aspirin treatment assignment, n (%)	1052 (49.9)	1033 (50.6)	1042 (50.7)	1320 (49.4)	1324 (50.8)	1303 (49.7)

Characteristic	Men			Women		
	T1, n=2,107	T2, n=2,043	T3, n=2,054	T1, n=2,672	T2, n=2,608	T3, n=2,621
Pulse Pressure, mean (SD)	60.7 (12.1)	62.4 (12.3)	65.7 (14.2)	57.9 (12.9)	60.2 (13.8)	64.2 (15.2)
Heart Rate, mean (SD)	69.4 (10.5)	68.9 (11.1)	68.4 (11.1)	72.6 (9.8)	72.2 (10.2)	71.3 (10.7)
Standard deviation of heart rate variability <sup>a</sup> , mean (SD)	5.4 (3.5)	5.7 (3.9)	6.1 (4.1)	5.0 (3.4)	5.3 (3.7)	5.6 (3.8)
Cognitive Performance						
3MS, mean (SD)	93.2 (4.5)	92.8 (4.7)	92.9 (4.6)	94.5 (4.2)	94.3 (4.2)	94.2 (4.3)
HVLT-R delayed recall, mean (SD)	7.4 (2.8)	7.3 (2.9)	7.3 (2.8)	8.4 (2.6)	8.4 (2.7)	8.3 (2.7)
SDMT, mean (SD)	36.3 (9.6)	35.8 (9.6)	35.0 (9.7)	38.9 (9.7)	38.6 (9.8)	37.5 (9.9)
COWAT, mean (SD)	11.6 (4.4)	11.5 (4.5)	11.6 (4.5)	12.7 (4.7)	12.7 (4.4)	12.7 (4.5)

<sup>a</sup>Over the period in which blood pressure variability was measured, baseline to the second annual visit.

Age was categorised based on the median age of participants, which was 74 years.

Ethno-racial group was based on self-report. Other ethno-racial group was defined as any individual category with less than 200 participants overall, which included Aboriginal or Torres Strait Islander, Native American, Native Hawaiian or Pacific Islander, multiple races or ethnic groups.

Diabetes was defined as a participants' report of diabetes mellitus or a fasting glucose level of  $\geq 126$  mg per deciliter ( $\geq 7$  mmol per liter) or receipt of treatment for diabetes.

Depression was defined as a Center for Epidemiological Studies Depression Scale 10 (CES-D-10) score of  $\geq 8$ .

Dyslipidemia was defined as serum cholesterol level of  $\geq 212$  mg per deciliter ( $\geq 5.5$  mmol per liter) in Australia and  $\geq 240$  mg per deciliter ( $\geq 6.2$  mmol per liter) in the U.S. or as a low-density lipoprotein level of  $> 160$  mg per deciliter ( $> 4.1$  mmol per liter); or taking cholesterol-lowering medication.

Chronic Kidney Disease was defined as eGFR  $< 60$  ml/min/1.73m<sup>2</sup> or albumin to creatinine ratio  $\geq 3$ mg/mmol.

SD: standard deviation.

**Table S2. Adjusted association between blood pressure variability (BPV) and incident dementia and cognitive decline in men and women, restricting the sample to only those participants whose use (or non-use) of antihypertensives was stable during the period when BPV was defined (from baseline to annual visit 2).**

	Men					Women				
	N	N, events	HR	95% CI	P	N	N, events	HR	95% CI	P
<b>Incident Dementia</b>	6589	162				8530	187			
T1	2375	46	Ref.			2914	61	Ref.		
T2	2161	42	0.97	0.64-1.48	0.89	2852	58	0.92	0.64-1.32	0.65
T3	2103	74	1.63	1.12-2.38	0.01	2764	68	1.01	0.71-1.43	0.97
<b>Incident Cognitive Decline</b>	5587	816				7273	980			
T1	1952	265	Ref.			2493	321	Ref.		
T2	1840	243	0.98	0.82-1.17	0.81	2409	301	0.97	0.83-1.13	0.69
T3	1795	308	1.32	1.12-1.57	0.001	2351	358	1.10	0.94-1.32	0.24

Adjusted for age, average systolic blood pressure, anti-hypertensive medications from baseline to annual visit 2, education, diabetes, depression, BMI, and statin medications.

HR: Hazard Ratio; 95% CI: 95% Confidence Interval.

**Table S3. Adjusted association between BPV estimated using average real variability (ARV) and coefficient of variation (CV) and incident dementia and cognitive decline in men and women.**

	Men					Women				
	N	N, events	HR	95% CI	P	N	N, events	HR	95% CI	P
<b>Incident Dementia</b>	7318	188				9282	208			
ARV, T1	2627	48	Ref.			3326	77	Ref.		
ARV, T2	2330	51	1.16	0.78-1.73	0.45	3001	67	0.95	0.68-1.32	0.75
ARV, T3	2361	89	1.86	1.30-2.66	0.001	2955	64	0.83	0.59-1.17	0.28
CV, T1	2442	50	Ref.			3095	67	Ref.		
CV, T2	2439	49	0.99	0.64-1.42	0.81	3094	71	1.01	0.72-1.41	0.97
CV, T3	2437	89	1.67	1.18-2.37	0.004	3093	70	0.94	0.67-1.31	0.71
<b>Incident Cognitive Decline</b>	6204	915				7901	1078			
ARV, T1	2237	309	Ref.			2830	358	Ref.		
ARV, T2	1958	249	0.92	0.78-1.09	0.31	2556	346	0.93	0.80-1.08	0.33
ARV, T3	2009	357	1.29	1.10-1.51	0.001	2515	374	1.10	0.95-1.28	0.19
CV, T1	2068	275	Ref.			2634	347	Ref.		
CV, T2	2068	286	1.04	0.88-1.23	0.61	2635	326	0.93	0.80-1.08	0.33
CV, T3	2068	354	1.28	1.09-1.50	0.002	2632	405	1.10	0.95-1.28	0.19

Adjusted for age, average systolic blood pressure, anti-hypertensive medications at baseline, education, diabetes, depression, BMI, and statin medications.



**Table S4. Adjusted association between blood pressure variability estimated from four time-points (baseline, annual visit 1, 2 and 3) and incident dementia (n=14,052) and cognitive decline (n=7,980) occurring after annual visit 3.**

	Men					Women				
	N	N, events	HR	95% CI	P	N	N, events	HR	95% CI	P
<b>Incident Dementia</b>	6184	110				7868	117			
T1	2073	23	Ref.			2632	39	Ref.		
T2	2053	35	1.38	0.82-2.34	0.23	2614	37	0.91	0.58-1.44	0.70
T3	2058	52	1.94	1.18-3.21	0.009	2622	41	0.85	0.54-1.33	0.47
<b>Incident Cognitive Decline</b>	3460	454				4520	559			
T1	1002	132	Ref.			1510	161	Ref.		
T2	1008	147	1.02	0.81-1.30	0.84	1504	185	1.13	0.91-1.40	0.26
T3	976	175	1.18	0.93-1.48	0.17	1506	213	1.22	0.99-1.51	0.07

Adjusted for age, average systolic blood pressure, anti-hypertensive medications at baseline, education, diabetes, depression, BMI, and statin medications.

**Table S5. Cox proportional hazards analysis for the association between blood pressure related measures and incident dementia and cognitive decline in men and women.**

Baseline characteristics	Men			Women		
	HR	95% CI	P	HR	95% CI	P
<b>Incident Dementia</b>						
Anti-hypertensive medications	1.14	0.86-1.52	0.37	1.12	0.85-1.48	0.42
High blood pressure (>140/90 mmHg)	0.95	0.71-1.26	0.70	0.93	0.71-1.23	0.62
Systolic blood pressure (mm Hg)	1.00	0.99-1.01	0.47	1.00	0.99-1.01	0.76
High systolic blood pressure (≥140 mm Hg)	0.95	0.72-1.27	0.75	0.92	0.70-1.21	0.55
Diastolic blood pressure (mm Hg)	0.99	0.98-1.01	0.43	1.00	0.98-1.01	0.58
High diastolic blood pressure (≥90 mm Hg)	0.96	0.62-1.51	0.88	1.00	0.67-1.52	0.98
<b>Incident Cognitive Decline</b>						
Anti-hypertensive medications	1.09	0.96-1.24	0.20	1.08	0.96-1.22	0.23
High blood pressure (>140/90 mmHg)	1.02	0.89-1.16	0.78	0.99	0.88-1.12	0.86
Systolic blood pressure (mm Hg)	1.00	1.00-1.00	0.89	1.00	1.00-1.01	0.55
High systolic blood pressure (≥140 mm Hg)	1.02	0.90-1.16	0.76	1.00	0.89-1.13	0.95
Diastolic blood pressure (mm Hg)	1.00	0.99-1.00	0.42	1.00	0.99-1.00	0.34
High diastolic blood pressure (≥90 mm Hg)	1.07	0.89-1.29	0.48	0.90	0.75-1.08	0.24

Adjusted for age


**Table S6. Cox proportional hazards analysis for the association between diastolic blood pressure variability and incident dementia and cognitive decline.**

BPV Tertiles	N	N, events	Adjusted age			Multivariate adjusted		
			HR	95% CI	P	HR	95% CI	P
<b>DEMENTIA</b>								
Men (n=7318)								
T1	2648	63	Ref.			Ref.		
T2	2451	56	0.89	0.61-1.29	0.53	0.86	0.59-1.24	0.41
T3	2218	69	1.18	0.84-1.65	0.35	1.15	0.82-1.62	0.42
Women (n=9282)								
T1	3049	52	Ref.			Ref.		
T2	3011	68	1.12	0.79-1.60	0.52	1.17	0.79-1.59	0.54
T3	3222	88	1.31	0.94-1.83	0.12	1.31	0.95-1.84	0.12
<b>COGNITIVE DECLINE</b>								
Men (n=6204)								
T1	2237	308	Ref.			Ref.		
T2	2064	282	0.97	0.82-1.14	0.71	0.97	0.83-1.14	0.71
T3	1887	316	1.07	0.92-1.26	0.37	1.08	0.92-1.26	0.34
Women (n=7901)								
T1	2550	329	Ref.			Ref.		
T2	2562	339	0.94	0.81-1.09	0.44	0.95	0.82-1.10	0.46
T3	2773	400	0.97	0.84-1.13	0.71	0.96	0.83-1.11	0.59

<sup>a</sup>Adjusted for age, average systolic blood pressure, anti-hypertensive medications at baseline, education, diabetes, depression, BMI, and statin medications.

**Figure S1. Study design showing the period when blood pressure variability (BPV) was measured, and assessment of incident dementia and cognitive decline.**

BPV was defined as the standard deviation of mean systolic blood pressure at baseline, year 1 and year 2 visits. For this analysis, individuals with cognitive decline or dementia before the year 2 annual visit were excluded, and dementia incidence and cognitive decline was assessed from year 2 onwards.



**Figure S2.** Overall Cumulative Incidence of Dementia (a) and Cognitive Decline (b) According to Blood Pressure

Variability Tertile.

